Today (9 May 2024) the Lung Research and Innovation Group (LRIG), of which Cystic Fibrosis Trust is a member, have published a ten-step plan to fix lung health by improving respiratory research and innovation.
The aim of this study is to measure the long-term safety, tolerability, and effectiveness of a combination of medicines (VX-121/TEZ/D-IVA) in people 1 year and older with CF. The treatment is made up of three medications: VX-121, tezacaftor and deutivacaftor. Deutivacaftor is a slightly modified version of ivacaftor that is potentially more stable in the body. This means deutivacaftor can be taken once a day instead of twice a day. People participating in the study will receive a single, daily dose of VX-121/TEZ/D-IVA in tablet form. Participants will be asked to visit the CF clinic 11 times over a period...
We spoke to Elaina, 24, about growing up with cystic fibrosis (CF), relationships when you have a chronic condition, and the challenges of being friends with people you can never meet.
As part of our ‘inside the lab’ series about CF researchers, we spoke to Trust-funded PhD student Charlotte about her CF research studies at the University of Sheffield and her experiences of attending the European Young Investigators Meeting in March this year.
